Why low-cost ketamine is still inaccessible to many with severe depression | The George Institute for Global Health
Why low-cost ketamine is still inaccessible to many with severe depression | The George Institute for Global Health
www.georgeinstitute.org.au Why low-cost ketamine is still inaccessible to many with severe depression | The George Institute for Global Health
A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.
You're viewing a single thread.
All Comments
1 comments